论文部分内容阅读
采用体外克隆形成培养技术研究维拉帕米（ＶＰＬ）联用阿霉素（ＡＤＭ）、长春新碱（ＶＣＲ）和足叶己甙（ＶＰ－１６）体外净化白血病细胞，结果显示：ＶＰＬ２．２μｍｏｌ／Ｌ能明显增加单一应用的不同浓度ＡＤＭ、ＶＣＲ或ＶＰ－１６对白血病细胞克隆形成单位（Ｌ－ＣＦＵ）的抑制作用，而不增加其对正常粒巨系克隆形成单位（ＧＭ－ＣＦＵ）的毒性。０．９２μｍｏｌ／ＬＡＤＭ、０．０２５０μｍｏｌ／ＬＶＣＲ及１．７０μｍｏｌ／ＬＶＰ－１６联合应用下，Ｌ－ＣＦＵ集落存活率为１１．６１％％，再联用２．２０μｍｏｌ／ＬＶＰＬ则为３．５２％；而相同条件下ＧＭ－ＣＦＵ集落存活率分别为３５．８１％及２６．０５％（与相应Ｌ－ＣＦＵ组相比，Ｐ＜０．０１），提示ＶＰＬ能明显增加上述化疗药物联合应用下的选择性体外净化白血病细胞作用。
In vitro culture of VPL was used to study the in vitro purification of leukemic cells with verapamil (ADM), vincristine (VCR) and etoposide (VP-16). The results showed that VPL2.2μmol / L can significantly increase the inhibitory effect of ADM, VCR or VP-16 on the formation of monocyte-derived leukemic cells (L-CFU) in a single application without increasing the inhibitory effect on the expression of GM-CFU toxicity. Under the combined application of 0.92μmol / L ADM, 0.0250μmol / LVCR and 1.70μmol / LVP-16, the survival rate of L-CFU colonies was 11.61%, and the combined use of 2.20μmol / LVPL was 3.52% , While the survival rates of GM-CFU colonies under the same conditions were 35.81% and 26.05% (P <0.01 compared with the corresponding L-CFU group), suggesting that VPL can significantly increase the combination of the above chemotherapy drugs Selective purification of leukemic cells in vitro.